Objective To systematically evaluate the efficacy and safety of memantine in the treatment of behavioral and psychological symptoms of dementia（ BPSD） in Alzheimer disease（ AD）. Methods Randomized controlled trials（ RCTs） on methadone for AD in BPSD were collected and retrieved from the databases of Medline， Embase， Cochrane Library（ CENTRAL）， CBMdisc， VIP and CNKI until February 2018. Two researchers independently screened literature， extracted data and evaluated the quality of the included studies. Then， Meta-analysis was performed using RevMan 5.3 software. Results A total of 12 RCTs were included， involving 3 982 patients. Patients in study group were treated with memantine and patients in contrd group were treated with placebo. Meta-analysis showed that memantine can improve the Neuropsychiatric Inventory（ NPI） score of AD patients（ SMD=-0.11， 95%CI=-0.17- -0.04，P=0.001）. There was no statistical difference between the two groups in the number of withdrawn and adverse events after treatment. The differences in the incidence of somnolence， hypertension and weight increased between the two groups were statistically significant. Conclusions Memantine can improve BPSD in AD patients， with good safety. However attention should be paid to the adverse events， including somnolence， hypertension and weight increased. Due to the limitation of quantity and quality of the included studies， the above conclusions are still needed to be verified with more high quality studies.